Close menu




December 2nd, 2020 | 11:59 CET

Deutsche Bank, dynaCERT, NEL ASA: Two paths lead to returns

  • Investments
Photo credits: pixabay.com

If you want to be successful in the stock market, you can pursue different investment styles: Known examples are value or growth strategies. Other investors, on the other hand, are more oriented towards market or chart techniques. Two approaches are promising here: Either one jumps on existing or emerging trends, or one buys completely counter-cyclically and tries to fish the bottom when prices are rising. The latter was a worthwhile undertaking in the case of the Deutsche Bank share. Within the past twelve months, the Deutsche Bank share has gained more than 40%. But what are the next steps for value?

time to read: 2 minutes | Author: Nico Popp
ISIN: CA26780A1084 , DE0005140008 , NO0010081235

Table of contents:


    Deutsche Bank: The proud money house and the gambler's paper

    From a technical chart point of view, the next significant resistance is above the EUR 10 mark. Taking this hurdle could be difficult for the price. However, there is further upside potential above this level. And what is the real picture? Most recently, Deutsche Bank was able to increase its earnings surprisingly significantly after nine months of the financial year. The investment banking business, in particular, performed well. At the same time, Deutsche Bank is busy saving money, revealing the whole dilemma: on the one hand, the formerly proud model bank must grow in order not to be swallowed, and on the other hand, costs must be reduced. The stock has become a speculative paper. Investment banking decides the fate of the Company.

    dynaCERT: Rollercoaster share picks up speed

    The dynaCERT share is also a volatile turnaround candidate. The Company has set itself the goal of retrofitting existing vehicle fleets with its catalytic converters and thus saving fuel and CO2. These catalysts bear the name HydraGEN and ensure that a mixture of air and hydrogen is fed to the engine, which results in the positive effects mentioned above, as confirmed by independent laboratories. The initial aim is to equip fleets in cities with the technology. In the past months, several customers have already been acquired. The fact that dynaCERT is part of the UN program "United 4 Smart Sustainable Cities" also helps with sales.

    Last year, the share went on a rollercoaster ride: between EUR 0.27 and 0.87 was traded. For a few days now, the stock has been bouncing back after a consolidation phase lasting several months. The market has come to realize that retrofitting existing combustion engines could be a sensible middle course to protect the climate. Only recently, an ARTE documentary on the climate sins of electric cars and wind turbines caused a stir (click here for a summary of the documentary). Due to its volatility and the low market penetration of the HydraGEN technology, the dynaCERT share is highly speculative. For this very reason, it can offer attractive opportunities to experienced investors.

    NEL ASA: From all-time high to an all-time high

    NEL ASA is another Company that stands for a green turnaround in transportation, outside the realm of classic electromobility. The Norwegians are responsible for the production, storage and distribution of hydrogen. Hydrogen is considered a potential fuel of the future. Unlike electric cars whose batteries have to be charged, hydrogen vehicles could be refueled at existing filling stations. The market believes this technology has a future and sent the stock up by a whopping 40% within a month.

    But the NEL Asa share is also a hot topic. From a technical chart point of view, it is noticeable that the value has hit its head twice beyond the EUR 2.40 mark. Although this resistance zone is not apparent in the long-term chart, traders with a short-term orientation, in particular, could see the latest price development as a warning signal.

    Momentum beats chart technique

    Regardless of whether Deutsche Bank or NEL ASA: At first glance, both stocks seem to have run hot. If the existing resistance is overcome, however, new potential can arise in both stocks - both comeback stories and hot trend stocks are difficult to stop with the appropriate momentum. The dynaCERT share is currently building this momentum. The leaving of the consolidation range, which exists since the end of August, could be a signal for chart-oriented traders.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read